Clinical trials
Phase 3 trials in Bosnia and Herzegovina
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
153 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 5 |
| 2007 | 8 |
| 2008 | 4 |
| 2009 | 8 |
| 2010 | 5 |
| 2011 | 9 |
| 2012 | 4 |
| 2013 | 7 |
| 2014 | 7 |
| 2015 | 12 |
| 2016 | 8 |
| 2017 | 11 |
| 2018 | 18 |
| 2019 | 7 |
| 2020 | 4 |
| 2021 | 8 |
| 2022 | 6 |
| 2023 | 7 |
| 2024 | 5 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 99 |
| Terminated | 27 |
| Active, not recruiting | 22 |
| Unknown status | 3 |
| Recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 25 |
| AbbVie | 16 |
| Pfizer | 10 |
| Celgene | 6 |
| Sanofi | 6 |
| Shire | 5 |
| Novo Nordisk A/S | 4 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 4 |
| Takeda | 4 |
| Biogen | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Crohn Disease | 16 |
| Breast Neoplasms | 15 |
| Multiple Sclerosis | 12 |
| Arthritis, Rheumatoid | 10 |
| Colitis, Ulcerative | 10 |
| Carcinoma, Non-Small-Cell Lung | 9 |
| Multiple Sclerosis, Relapsing-Remitting | 7 |
| Epilepsy | 6 |
| Joint Diseases | 5 |
| Arthritis | 4 |
Trials
Showing 76 to 100 of 153. Each trial links to its page on Pharma Observatory.
53 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.